M. Schlederer

YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1 mediated reprogramming of bone mesenchymal stem cells

The paper shows that IGF-1 reprograms bone mesenchymal stem cells in EWS::FLI1-mutant mice, leading to tumor formation, with Yap1 playing a central role, and suggests combined IGF-1R and YAP/TEAD inhibition as a potential treatment.

Cell-autonomous GP130 activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment

This study shows that activating GP130 in prostate epithelial cells suppresses tumor growth through senescence and immune activation, suggesting a new therapeutic approach.

JUN mediates senescence and immune cell recruitment to prevent prostate cancer progression

This study shows JUN suppresses prostate cancer progression by inducing senescence and immune cell recruitment, with JUN depletion accelerating tumor growth.

STAT3 restricts prostate cancer metastasis and antiandrogen resistance by controlling LKB1/CREB signaling pathway

This study identifies STAT3's role in restricting prostate cancer metastasis and antiandrogen resistance by regulating the LKB1/CREB signaling pathway in mouse models and human patients.

Thyroid and androgen receptor signaling are antagonized by CRYM in prostate cancer

This study shows that CRYM antagonizes thyroid and androgen signaling in prostate cancer and correlates with prognosis and PET imaging biomarkers.

STAT3-dependent systems-level analysis reveals PDK4 as an independent predictor of biochemical recurrence in prostate cancer

The paper identifies PDK4 as an independent prognostic marker for prostate cancer recurrence using gene co-expression networks and proteomics data.